Protein-Free Efavirenz Concentrations in Cerebrospinal Fluid and Blood Plasma Are Equivalent: Applying the Law of Mass Action To Predict Protein-Free Drug Concentration
暂无分享,去创建一个
[1] Jintanat Ananworanich,et al. Central nervous system viral invasion and inflammation during acute HIV infection. , 2012, The Journal of infectious diseases.
[2] Michael Rayment,et al. Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.
[3] I. Grant,et al. Low Cerebrospinal Fluid Concentrations of the Nucleotide HIV Reverse Transcriptase Inhibitor, Tenofovir , 2012, Journal of acquired immune deficiency syndromes.
[4] U. Holzgrabe,et al. Overton's Rule Helps To Estimate the Penetration of Anti-Infectives into Patients' Cerebrospinal Fluid , 2011, Antimicrobial Agents and Chemotherapy.
[5] J. Baeten,et al. Characteristics of HIV-1 Serodiscordant Couples Enrolled in a Clinical Trial of Antiretroviral Pre-Exposure Prophylaxis for HIV-1 Prevention , 2011, PloS one.
[6] C. Hendrix,et al. The Male Genital Tract Is Not a Pharmacological Sanctuary From Efavirenz , 2011, Clinical pharmacology and therapeutics.
[7] R. Haubrich,et al. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. , 2011, The Journal of antimicrobial chemotherapy.
[8] David V Glidden,et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.
[9] D. Meyers,et al. A highly sensitive ultra performance liquid chromatography-tandem mass spectrometric (UPLC-MS/MS) technique for quantitation of protein free and bound efavirenz (EFV) in human seminal and blood plasma. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[10] Edward H. Kerns,et al. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.
[11] F. Sörgel,et al. Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections , 2010, Clinical Microbiology Reviews.
[12] Lynn Morris,et al. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.
[13] Amalio Telenti,et al. Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .
[14] S. Broder,et al. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. , 2010, Antiviral research.
[15] I. Grant,et al. Low atazanavir concentrations in cerebrospinal fluid , 2009, AIDS.
[16] Peter Reiss,et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.
[17] B. Caffo,et al. Effect of Semen Sampling Frequency on Seminal Antiretroviral Drug Concentration , 2008, Clinical pharmacology and therapeutics.
[18] K. Korzekwa,et al. Impact of pH on plasma protein binding in equilibrium dialysis. , 2008, Molecular pharmaceutics.
[19] B. Brew,et al. Biomarkers of HIV related central nervous system disease , 2008, International review of psychiatry.
[20] I. Grant,et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. , 2008, Archives of neurology.
[21] Douglas D. Richman,et al. Antiretroviral Treatment of Adult HIV Infection , 2008 .
[22] R. Ellis,et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV , 2005, AIDS.
[23] J. McArthur. HIV dementia: an evolving disease , 2004, Journal of Neuroimmunology.
[24] K. Marder,et al. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. , 2004, Archives of neurology.
[25] C. Petropoulos,et al. Natural Variation of Drug Susceptibility in Wild-Type Human Immunodeficiency Virus Type 1 , 2004, Antimicrobial Agents and Chemotherapy.
[26] V. Miller,et al. Protein binding in antiretroviral therapies. , 2003, AIDS research and human retroviruses.
[27] A. Fura,et al. Shift in pH of biological fluids during storage and processing: effect on bioanalysis. , 2003, Journal of pharmaceutical and biomedical analysis.
[28] N. Sacktor. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. , 2002, Journal of neurovirology.
[29] D I Stuart,et al. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. , 2000, Structure.
[30] K. Tashima,et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. , 1999, The Journal of infectious diseases.
[31] K. P. Murphy,et al. Evaluation of linked protonation effects in protein binding reactions using isothermal titration calorimetry. , 1996, Biophysical journal.
[32] C. Petito,et al. Blood‐brain barrier abnormalities in acquired immunodeficiency syndrome: Immunohistochemical localization of serum proteins in postmortem brain , 1992, Annals of neurology.
[33] R. Rhodes. Evidence of Serum-Protein Leakage Across the Blood-Brain Barrier in the Acquired Immunodeficiency Syndrome , 1991, Journal of neuropathology and experimental neurology.
[34] L. Resnick,et al. Early penetration of the blood‐brain‐barrier by HIV , 1988, Neurology.
[35] I. Elovaara,et al. CSF protein and cellular profiles in various stages of HIV infection related to neurological manifestations , 1987, Journal of the Neurological Sciences.